Time filter

Source Type

May-Concha I.,Instituto Nacional Of Salud Publica Crisp Insp | Rojas J.C.,Colegio de Mexico | Cruz-Lopez L.,Colegio de Mexico | Millar J.G.,University of California at Riverside | Ramsey J.M.,Instituto Nacional Of Salud Publica Crisp Insp
Medical and Veterinary Entomology | Year: 2013

In this study, we evaluated the responses of Triatoma dimidiata Latreille (Hemiptera: Reduviidae) to volatiles emitted by conspecific females, males, mating pairs and metasternal gland (MG) extracts with a Y-tube olfactometer. The volatile compounds released by mating pairs and MGs of T. dimidiata were identified using solid-phase microextraction and coupled gas chromatography-mass spectrometry (GC-MS). Females were not attracted to volatiles emitted by males or MG extracts; however, they preferred clean air to their own volatiles or those from mating pairs. Males were attracted to volatiles emitted by males, females, mating pairs, pairs in which the male had the MG orifices occluded or MG extracts of both sexes. However, males were not attracted to volatiles emitted by pairs in which the female had the MG orifices occluded. The chemical analyses showed that 14 and 15 compounds were detected in the headspace of mating pairs and MG, respectively. Most of the compounds identified from MG except for isobutyric acid were also detected in the headspace of mating pairs. Both females and males were attracted to octanal and 6-methyl-5-hepten-2-one, and males were attracted to 3,5-dimethyl-2-hexanol. Males but not females were attracted to a seven-compound blend, formulated from compounds identified in attractive MG extracts. © 2012 The Royal Entomological Society.


Viotti R.,Hospital Interzonal General Of Agudos Higa Eva Peron | Alarcon De Noya B.,Central University of Venezuela | Araujo-Jorge T.,Fundacao Oswaldo Cruz Instituto Oswaldo Cruz FIOCRUZ IOC | Grijalva M.J.,Pontifical Catholic University of Ecuador | And 9 more authors.
Antimicrobial Agents and Chemotherapy | Year: 2014

Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients. Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Loading Instituto Nacional Of Salud Publica Crisp Insp collaborators
Loading Instituto Nacional Of Salud Publica Crisp Insp collaborators